Peripheral Leukocyte Apoptosis in Patients with Parkinsonism: Correlation with Clinical Characteristics and Neuroimaging Findings

Table 1

Demographic data of patients with PD and controls.

Clinical demographics	PD (𝑛=55)	Control (𝑛=37)	𝑃
Age (year) (mean ± SD)	59.9 ± 10.9	62.9 ± 6.3	0.136
Sex (M, F)	22, 33	18, 19	0.089
White blood cells (×10^3/mL)^#	5.60 (5.00, 6.80)	6.05 (4.88, 8.43)	0.250
Red blood cells (×10^4/mL)^#	4.78 (4.42, 5.08)	4.41 (4.09, 5.00)	0.410
Platelet counts (×10^4/mL)^#	232 (200, 306)	223 (173, 276)	0.156
Duration of disease (years)^#	2.5 (1.0, 5.5)
UPDRS I^#	3.0 (1.0, 6.0)
UPDRS II^#	10.0 (4.0, 16.0)
UPDRS III^#	22.0 (14.0, 34.0)
UPDRS total^#	33.0 (20.0, 54.0)
Modified H & Y^# (maximum stage is 5)	1.75 (1.0, 3.0)
S & E^#(minimum point is 0 suggesting vegetative functions)	90.0 (77.5, 100.0)
TRODATE R^#	1.45 (1.24, 1.62)
TRODATE L^#	1.37 (1.23, 1.53)

UPDRS: Unified Parkinson’s Disease Rating Scale; modified H & Y: modified Hoehn and Yahr Staging Scale; S & E: Schwab and England Activities of Daily Living Scale.
^#Median (IQR): IQR: interquartile range.